They have been extensively characterized to be involved in many aspects of AML biology, and to be a therapeutic target, which led to the clinical development of several FLT3 inhibitors for the treatment of FLT3-ITD-positive AML [5–8]. The gene discussed is FLT3; the disease is acute myeloid leukemia.